Effect of Sacubitril/Valsartan on Cardiac Function in Hypertensive Patients Stratified by BMI: A Real World Study

NCT05498675 · tracked via the Priya Life Science China tracker

Sponsor

Beijing Friendship Hospital

Phase

Observational

Started

2021-09-01

Last updated

2025-02-13

Condition(s) studied

Sacubitril/ValsartanHypertensionObesity

Investigational drug(s) / intervention(s)

Sacubitril / Valsartan Oral Tablet [Entresto]ACEI/ARB

Sacubitril / Valsartan Oral Tablet [Entresto]: There is no treatment allocation. Patients administered sacubitril / valsartan oral tablet (Entresto) 200mg 1/day by prescription that have started before inclusion of the patient enrolled into the study and defined as sacubitril/valsartan group.

ACEI/ARB: There is no treatment allocation. Patients administered angiotensin-converting enzyme inhibitors/angiotensin II receptor antagonists (ACEI/ARB) by prescription that have started before inclusion of the patient enrolled into the study and defined as ACEI/ARB group. Including: benazepril, captopril, enalapril, fosinopril, lisinopril, moexipril, perindopril, quinapril, ramipril, trandolapril, azilsartan, candesartan, eprosartan, irbesartan, losartan, olmesartan, telmisartan, valsartan.

Study summary

The purpose of this study is to investigate the effect of sacubitril/valsartan on cardiac function assessed by cardiac magnetic resonance (CMR) in hypertensive patients stratified by BMI.

Eligibility

Sex

ALL

Min age

18 Years

Max age

70 Years

Healthy volunteers

Inclusion Criteria: * Patients with essential hypertension * 18-70 years old * No major barriers to provide written consent Exclusion Criteria: * Secondary hypertension, except because of sleep apnea * cardiovascular disease (myocardial infarction, heart failure, stroke or coronary revascularization) within 6 months * Severe concomitant diseases (autoimmune disease, malignancy, late stage of liver diseases, respiratory diseases and digestive diseases) * Unable to understand or comply with the study procedures

Primary outcome measure(s)

Changes on left ventricular ejection fraction (LVEF) — 6 months
Changes on LVEF in % assessed with the use of cardiac magnetic resonance (CMR).

Trial sites (1)

Facility	City	Region	Status
Beijing Friendship Hospital, Capital Medical University	Beijing	Beijing Municipality	Recruiting

More Beijing Friendship Hospital trials in China

Retrospective Analysis of Early Gastric Cancer Patients Based on Prospective Clinical Dataset Recruiting

Beijing Friendship Hospital Metabolic Surgery Database Recruiting

BeijngFH Health Cohort Study Recruiting

Clinical Classification of MAFLD Based Liver Biopsy Starting soon

Segmental Resection Combined With DEP Regimen for EBV-HLH Patients With Intestinal Involvement Starting soon

Other trials for the same condition

LLM-CoManage: Large Language Model-Enabled Co-Management of Hypertension, Diabetes, and Dyslipidemia Active, not recruiting

Clinical Analysis of the Antihypertensive Effect of Laparoscopic Peripheral Nerve Blockade of the Renal Artery in Patients With Retroperitoneal Disease and Hypertension Recruiting

Goal Commitment and Proactive Health Behavior in Chronic Disease Patients Recruiting

A Study of Eloralintide (LY3841136) in Participants With Obstructive Sleep Apnea and Obesity or Overweight Recruiting

Food Intake-Related Brain and Metabolic Responses in Obesity Recruiting

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT05498675 on ClinicalTrials.gov ↗ ← All trials in China